REX to showcase at ISCoS and ASIA, Montreal

14 May 2015

Rex Bionics plc

("Rex Bionics" or the "Company")

Rex Bionics to showcase REX robotic device at the 4th ISCoS and ASIA Joint Scientific Meeting in Montreal, Canada, 14th-16th May 2015

Rex Bionics plc (AIM: RXB), the pioneer of the REX robot technology (REX) that enhances the mobility of wheelchair users, will be attending the 4th ISCoS and ASIA joint Scientific Meeting at The Fairmount Queen Elizabeth Hotel in Montreal, Canada on 14th to 16th May.

This will be the first exhibition of REX in Canada and the Rex Bionics team will be demonstrating the benefits of REX for wheelchair users in addition to highlighting its applicability in Robot Assisted Physiotherapy (RAP). The REX can be seen on booth number 17.

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 748 3 167851

Peter Worrall, Chief Financial Officer

+44 (0) 142 864 5416

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/Giles Balleny

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville

[email protected]

+44 (0) 203 709 5700

About Rex Bionics

Rex Bionics (AIM: RXB) is the UK AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists. 

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits. 

REX can be used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options. 

In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

REX is not approved for At-Home use in the United States of America.

Ends